2004-2014年欧盟/欧洲经济区国家侵袭性脑膜炎球菌病流行病学
该研究分析2004-2014年欧盟/欧洲经济区国家侵袭性脑膜炎球菌病监测数据,按年龄、性别、血清群、国家和结局分层。总年报告率为0.9/10万,每年下降6.6%(95%CI:-8.0%;-5.1%),婴儿报告率最高(16.0/10万)。B群占全部病例74%,B群和C群呈下降趋势,Y群呈上升趋势;引入MCC疫苗的国家C群报告率下降。
要点
- 总年报告率为0.9/10万,每年下降6.6%(95%CI:-8.0%;-5.1%)。
- 婴儿年报告率最高(16.0/10万),所有<50岁年龄组均呈下降趋势。
- B群占全部病例74%,B群和C群报告率下降,Y群上升。
核心结论
- 研究结果支持常规MCC疫苗接种是C群报告率下降趋势驱动因素的证据。
- 在生命第一年接种B群疫苗可能有助于减轻该血清群所致IMD负担。
- 血清群特异性报告率趋势变化凸显需要高质量监测数据以准确评估IMD流行病学变化、已实施疫苗的效果和影响以及未来疫苗需求。
研究设计与样本
- 分析2004-2014年欧盟/欧洲经济区国家IMD监测数据,按年龄、性别、血清群、国家和结局分层。
- 采用年报告率对数线性回归分析估计年报告率百分比变化。
- 按将MCC疫苗纳入常规免疫规划的年份对国家分组。
主要发现
- 总年报告率为0.9/10万,每年下降6.6%(95%CI:-8.0%;-5.1%)。
- 婴儿年报告率最高(16.0/10万),所有<50岁年龄组均呈下降趋势。
- B群占全部病例74%,并在所有年龄组中占多数病例。
- B群和C群报告率呈下降趋势,Y群呈上升趋势。
- 在2004年前和2004-2014年间引入MCC疫苗接种的国家C群报告率呈下降趋势,而未开展常规MCC疫苗接种的国家无此趋势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive meningococcal disease (IMD) is a major cause of bacterial meningitis and septicaemia although infection by some serogroups may be prevented through vaccination. We aimed to describe the epidemiology of IMD in EU/EEA countries during 2004-2014 to monitor serogroup- and age-specific trends, and compare country trends by the period of meningococcal C conjugate (MCC) vaccine introduction. METHODS: We analysed IMD surveillance data by age, gender, serogroup, country and outcome. We estimated the percentage change in annual notification rate (NR), using linear regression analysis of the log of the annual NR. We grouped countries by the year they introduced MCC vaccination into their routine immunisation programmes. RESULTS: The overall NR was 0.9/100 000 population, and decreased 6.6% (95%CI: -8.0%;-5.1%) annually. Infants had the highest NR (16.0/100 000), and there were decreasing trends in all age groups <50years. Serogroup B (SgB) caused 74% of all cases, and the majority of cases in all age groups. There were decreasing trends in SgB and serogroup C (SgC) and an increasing trend in serogroup Y. Countries that introduced MCC vaccination before, and between 2004 and 2014, had decreasing trends in NR of SgC, but not countries without routine MCC vaccination. CONCLUSIONS: Our findings support evidence that routine MCC vaccination was the driving force behind the decreasing SgC trend. Vaccinating against SgB in the first year of life could help reduce the burden of IMD due to this serogroup. Changing serogroup-specific NR trends highlight the need for high-quality surveillance data to accurately assess the changing epidemiology of IMD, the effectiveness and impact of implemented vaccines, and the need for future vaccines.
引用
- Whittaker R, Dias JG, Ramliden M, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014. Vaccine. 2017. PMID: 28314560. doi:10.1016/j.vaccine.2017.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。